Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Anxiety, Generalized Anxiety Disorder, Generalized Anxiety
Interventions: Cranial Electrotherapy Stimulator (CES) Device; Device
Lead sponsor: ProofPilot; Industry
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions: peginesatide, Epoetin Alfa; Drug
Lead sponsor: Affymax; Industry
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 89
States / cities: Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more

Conditions: Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: ponsegromab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more

Conditions: Nicotine Dependence
Interventions: Nicotine, Vaporizer Device, Salt-HIgh Nicotine Unflavored (Product B), Free-Low Nicotine Tobacco Flavored (Product C), Salt-High Nicotine Tobacco Flavored (Product D); Drug · Device
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell
Interventions: Vemurafenib, Obinutuzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 9
States / cities: New Haven, Connecticut • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more

Conditions: Urinary Bladder Neoplasms
Interventions: TAR-200, Cetrelimab; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more

Conditions: Anxiety Disorders and Symptoms
Interventions: Maya mobile app, Social Support, Gain Framed, Loss Framed; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 25 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Neoplasms
Interventions: Semi-structured interview, Developed survey completion, Systems of Belief Inventory (SBI-15R); Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Chronic Pain, Opioid Use
Interventions: Opioid Phase; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Heavy Episodic Drinking
Interventions: Alcohol administration; Other
Lead sponsor: New York University; Other
Eligibility: 21 Years to 29 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Glanzmann Thrombasthenia
Interventions: HMB-001; Drug
Lead sponsor: Hemab ApS; Industry
Eligibility: 18 Years to 67 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 5
States / cities: La Jolla, California • New Orleans, Louisiana • Rochester, Minnesota + 2 more

Conditions: Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor
Interventions: Tamoxifen; Drug
Lead sponsor: AC Camargo Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Retatrutide, Semaglutide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 38
States / cities: Birmingham, Alabama • Escondido, California • Long Beach, California + 34 more

Conditions: Hidradenitis Suppurativa
Interventions: Placebo, LY3041658; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Cancer
Interventions: Sleep coaching, Sleep education; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Type 1 Diabetes Mellitus
Interventions: Allogenic Human Islet Cells, Immunosuppressive Agents, Gastrin 17; Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 68 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Hepatic Insufficiency, Liver Diseases, Pharmacokinetics, Drug Metabolism
Interventions: Sevabertinib; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Gout
Interventions: Pegloticase; Biological
Lead sponsor: John Sundy; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pelizaeus-Merzbacher Disease
Interventions: Not listed
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 6 Months to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: working memory and attention; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Progressive Supranuclear Palsy (PSP)
Interventions: ABBV-8E12, Placebo solution for IV infusion on Day 15; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 40 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more

Conditions: Anesthesia
Interventions: Survey; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: PreDiabetes, Diet, Healthy, Nutritional and Metabolic Diseases
Interventions: Whole Foods for Families; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 6 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Sleep, THC, Marijuana, Cannabis
Interventions: Dronabinol; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Brain Stimulation & Generalized Anxiety Study

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

Mobile Cognitive Behavior Therapy Targeting Anxiety Disorders

Study to Identify and Measure the Values and Palliative Care Pref. of Hindu Patients and Their Caregivers

Neuroimaging of Opioid Phase (OPAL)

Understanding the Associations Between Romantic Relationship Conflict, Psychophysiological Responding and Alcohol Misuse Among Emerging Adults

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

A Study of LY3041658 in Adults With Hidradenitis Suppurativa

Pilot Study of App-delivered Sleep Coaching Among Cancer Survivors and Their Partners

Islet Cell Transplant for Type 1 Diabetes

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

Analysis of Electrocorticographic Signals

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Survey of Anesthesiology Residents' Perceptions of Critical Care Medicine as a Career

Whole Food for Families: A Pilot RCT of a Dietary Guidelines-Based Intervention to Prevent Type 2 Diabetes

Tetrahydrocannabinol (THC) and Sleep